Molina Healthcare reported $11.1 billion in revenue and $38 million in profit for the third quarter. Those results trailed the prior-year period, with profit roughly half of what Molina posted the year before. The company reaffirmed its 2026 financial outlook after releasing results; investors reacted by pushing Molina’s stock down about 5% in after-hours trading. Analysts described the quarter as mixed — revenue and earnings beat some expectations but signal deterioration versus the prior year.
The company’s executives framed the quarter through the lens of its concentration in Medicaid, arguing that signs of reimbursement improvement should support recovery in 2027. Yet near-term metrics remained pressured. Enterprise-wide medical loss ratio, a common measure of spending on patient care, was reported at 92.9% for the period.
Medicaid remains central to Molina’s business: the insurer said the program accounts for roughly 90% of its membership and almost 80% of its premiums. In Q3, the Medicaid segment posted a medical loss ratio of 93%, higher than Wall Street anticipated. Molina’s CFO told investors that outpatient utilization and spending on high-cost drugs stayed elevated and were key drivers of the MLR increase.
The study team observed membership shifts as another factor: analysts suggested ongoing attrition has left Molina with a smaller, sicker Medicaid population, increasing per-member costs. The company also pointed to the launch of a new Medicaid contract in Florida focused on children with complex needs as adding to spending in the quarter.
Following Q3, Molina raised its full-year medical cost trend assumption from 5% to 5.5%. The firm now expects state payment rate adjustments to net about 4.5% for the current year, up from a prior 4% expectation. CEO Joe Zubretsky projected that state reimbursement rates should reach about 6% in 2027. Because the majority of Molina’s book renews in January and the insurer has draft rates for most contracts, management expressed confidence that aggregate Medicaid reimbursement will cover spending in 2027.
Molina also quantified the expected enrollment impact from federal work requirements tied to recent legislation. The company estimates it will lose roughly 6% of its Medicaid enrollees — approximately 260,000 people — next year because of those requirements. On a state-by-state basis, the insurer cited Nebraska’s early experience as “rather moderate” so far, noting that many initial denials reflected applicants’ failure to provide verification documentation.
Molina’s Medicare Advantage business posted an MLR that was worse than analyst expectations, though executives maintained it aligned with the company’s internal forecasts. The insurer reported strength in its dual-eligible business, which helped offset losses coming from its MA prescription drug products. Management said Molina will exit the MA Part D prescription drug line next year. That decision reflects operational choices to limit exposure where performance lagged internal targets.
The insurer’s Affordable Care Act plans reported a medical loss ratio of 92.5%, consistent with analyst models. Molina acknowledged that the ACA exchanges have been a source of pressure during 2026. The company retained a higher-than-expected share of high-acuity members after more generous plan subsidies were reduced, producing enrollment turbulence and a greater concentration of members on costly specialty drugs, including therapies for HIV and cancer.
To address that mismatch between risk and membership acuity, Molina trimmed its ACA footprint from 14 states to seven for 2027. Executives said the narrower footprint will help the insurer enter the year with risk scores more aligned to the actual health status of its enrollees and position the business to return to profitability in 2027; Molina expects the ACA segment to operate at a loss in 2026.
The broader Medicaid market showed similar signs of stabilization in Q3, with other large insurers reporting better-than-expected Medicaid performance driven by state rate increases and moderating medical cost trends. Still, the industry faces a major policy uncertainty: the GOP “Big Beautiful Bill” ties Medicaid eligibility to work, education or volunteer hours, a change projected to remove millions from the rolls over time.
Molina emphasized that states retain flexibility in implementing work requirements and that early state-level experience, including Nebraska’s initial rollout, has been relatively modest in scale. Even so, management acknowledged the reform could materially reduce enrollment across the Medicaid market, creating ongoing volatility for managed care plans that rely heavily on program membership and the risk pool it provides.
The company provided revenue, profit, MLRs and updated trend and rate assumptions, but the report did not detail the specific drivers behind outpatient and specialty drug spending line-by-line. The source did not report granular utilization metrics, precise membership churn rates by state beyond the high-level 6% national estimate tied to work requirements, or the exact timing and terms of each state draft rate that underlie Molina’s 2027 confidence.
Open questions remain that the company and industry will need to answer in coming quarters: how quickly outpatient and high-cost drug trends will moderate; whether draft state rates solidify at projected levels; and how implementation of work requirements will differ across states and over time. The report ends with Molina reiterating 2026 guidance and projecting Medicaid reimbursement coverage in 2027, but the company’s cautious near-term stance — and investor reaction — reflect those unresolved variables.